Korean J Pediatr.
2008 Jun;51(6):616-621. 10.3345/kjp.2008.51.6.616.
Interpretation of screening for congenital adrenal hyperplasia in preterm infants
- Affiliations
-
- 1Department of Pediatrics, Seoul National University, College of Medicine, Seoul, Korea. chshinpd@snu.ac.kr
- 2Department of Laboratory Medicine, Seoul National University, College of Medicine, Seoul, Korea.
- KMID: 2280297
- DOI: http://doi.org/10.3345/kjp.2008.51.6.616
Abstract
-
PURPOSE: This study was undertaken to identify factors that influence 17-OHP levels in preterm infants and to suggest a reasonable follow-up schedule of screening for congenital adrenal hyperplasia (CAH) in preterm infants.
METHODS
The 17-OHP concentrations in filter paper blood spots of 427 preterm infants were obtained. The effects of gestational age (GA), systemic diseases, and antenatal dexamethasone on screening and follow-up 17-OHP values were investigated.
RESULTS
The screening 17-OHP values were markedly variable (range: 0.1-143.3 ng/mL). The screening 17-OHP levels were negatively correlated with GA (r=-0.535, P<0.01). In infants with GA <32 weeks, the screening 17-OHP levels were significantly higher in sick infants or infant with hypotension than in healthy infants. The screening values of prenatal dexamethasone-treated infants had a tendency to be low. In infants with initial 17-OHP values > or =20 ng/mL, the intervals until rescreening 17-OHP <10 ng/mL or serum 17-OHP <20 ng/mL were negatively correlated with GA (r=-0.541, P<0.01) and were prolonged in infants with bronchopulmonary dysplasia (P<0.01). None of the preterm infants were confirmatively diagnosed with CAH.
CONCLUSION
The 17-OHP values of preterm infants were influenced by GA, prenatal dexamethasone, and postnatal diseases. Because the 17-OHP vlues of preterm infants were markedly variable, a follow-up schedule should be developed considering both 17-OHP values and clinical status.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Adrenal and thyroid function in the fetus and preterm infant
- Cutoff Value of 17-Hydroxyprogesterone Screening Test for Congenital Adrenal Hyperplasia According to Birth Weight
- A Case of Congenital Lipoid Adrenal Hyperplasia: Early Diagnosis by Using Computed Tomography
- A Cost-Benefit Analysis of Neonatal Screening Tests for Maple Syrup Urine Disease, Homocystinuria, Galactosemia, and Congenital Adrenal Hyperplasia
- Establishment of the Separate Cutoff Values of 17-alpha-hydroxyprogesterone in Neonatal Screening Program for Congenital Adrenal Hyperplasia according to Birth Weight
